B cells may help predict risk of colitis from immunotherapy
Researchers at The University of Texas MD Anderson Cancer Center have identified a previously unknown role for B cells, adaptive immune cells, in triggering and sustaining colitis as a side effect of immune checkpoint inhibitors, a widely used form of cancer immunotherapy.
<p>Researchers at The University of Texas MD Anderson Cancer Center have identified a previously unknown role for B cells, adaptive immune cells, in triggering and sustaining colitis as a side effect of immune checkpoint inhibitors, a widely used form of cancer immunotherapy.</p>